PURPOSE To highlight innovations in ophthalmic oncology through histiocytosis advancements. DESIGN Perspective and retrospective review. METHODS The literature outlining the recent advancements in histiocytosis and ocular oncology were reviewed and combined with trial data and personal recollection. Intersections between these two fields were discussed. RESULTS The understanding of genetic mutations in disease-both in which cells they occur and the timing of mutation development-has expanded in tandem for the fields of ophthalmic oncology and histiocytosis. Similarly, advancements in diagnostic and treatment technology in one field can help patients in the other. For example, in one study, cell-free DNA testing reliably detected mutations in 14 of 18 (78%) patients with suspected histiocytosis. This technique has also been used in ophthalmic oncology as an alternative to invasive biopsy to avoid the risk of tumor externalization, vision impairment, and other side effects. These and other advancements, have allowed both fields to utilize targeted agents to successfully treat diseases with an actionable mutation; or deliver more targeted chemotherapy via the intraarterial technique. CONCLUSIONS The explosion of molecular genetics technology and targeted therapies has revolutionized cancer treatment, including histiocytosis and ophthalmic oncology. Recent progress in both fields has shown how these seemingly disparate areas have many intersections, and this speaks to the collaborative spirit that is inherent in clinical research.

中文翻译：

---

组织细胞增多症进展平行眼科创新。LXXXI 爱德华·杰克逊纪念讲座。


目的 通过组织细胞增多症的进步突出眼科肿瘤学的创新。设计 观点和回顾性评价。方法 回顾了概述组织细胞增多症和眼肿瘤学最新进展的文献，并结合试验数据和个人回忆。讨论了这两个领域之间的交集。结果对疾病中基因突变的理解——包括它们发生在哪些细胞中以及突变发展的时间——已经扩展到眼科肿瘤学和组织细胞增多症领域。同样，一个领域的诊断和治疗技术的进步可以帮助另一个领域的患者。例如，在一项研究中，游离 DNA 检测可靠地检测到 18 名疑似组织细胞增多症患者中的 14 名 （78%） 的突变。该技术也已用于眼科肿瘤学，作为侵入性活检的替代方法，以避免肿瘤外化、视力障碍和其他副作用的风险。这些和其他进步使这两个领域都能够利用靶向药物成功治疗具有可操作突变的疾病;或通过动脉内技术提供更有针对性的化疗。结论 分子遗传学技术和靶向治疗的爆炸式增长彻底改变了癌症治疗，包括组织细胞增多症和眼科肿瘤学。这两个领域的最新进展表明，这些看似不同的领域有许多交叉点，这说明了临床研究中固有的合作精神。